Short-acting neuromuscular blocking drugs are administered most appropriately as infusions based upon pharmacokinetic characteristics. A new short-acting non-depolarizing neuromuscular blocker, mivacurium, has been under clinical trial for 2 years. It is a synthetic bisbenzylisoquinolinium diester. Its clinical neuromuscular pharmacology has been reported elsewhere [1] [2] [3] . It is hydrolysed by human plasma cholinesterase at approximately 88 % of the rate of suxamethonium. In an intubating dose (2-3 x ED 95 ), its duration is twice that of suxamethonium and approximately 33-50% that of equipotent doses of atracurium and vecuronium. Blockade with Mivacurium is also readily antagonized with anticholinesterases. The ED 95 (evoked thumb adduction at 0.15 Hz) under nitrous oxideoxygen-opioid anaesthesia is 0.08 mg kg" 1 . This study was undertaken to delineate the clinical pharmacology of a continuous infusion of mivacurium and to compare it with data we obtained from similar studies of atracurium and vecuronium.
SUMMARY

Mivacurium chloride (BW B1090U) is a new, short-acting non-depolarizing neuromuscular blocking agent. It is a synthetic bis-benzylisoquinolinium diester, which is hydrolysed rapidly by plasma cholinesterase. This study compares mivacurium, atracurium and vecuronium by continuous i. v. infusion. The duration of mivacurium infusion ranged from 29.5 to 286 min. The steady state infusion rates necessary to maintain 95 (SEM 4)% twitch sup-
Group I (mivacurium). Seventy-two ASA I-II. patients aged 18-49 yr and weighing 58-86 kg were studied. All patients gave written informed consent to the study which was approved by the Institution's Subcommittee on Human Studies. . Anaesthesia was maintained with 66% nitrous oxide in oxygen. Tracheal intubation was accomplished either under topical analgesia with 4% lignocaine or following a bolus dose of mivacurium. Ventilation was controlled to maintain arterial or end-tidal Pco 2 within the normal range. Body temperature was maintained at 35-37 °C. Additional increments of thiopentone and fentanyl were given to maintain adequate anaesthesia and stable arterial pressure and heart rate. Force of thumb adduction was measured with a transducer (Grass FT 10) and recorded continuously in response to ulnar nerve stimulation at 0.15 Hz in a manner described earlier [4] using a Grass S88 stimulator via an isolation unit and two 23-gauge steel percutaneous needle electrodes.
After stable control evoked twitch, arterial pressure and heart rate were obtained, mivacurium was injected i.v. to four subgroups of patients. Each subgroup received an initial bolus dose of 0.1,0.15, 0.2 or 0.25 mg kg" 1 to determine the influence of the size of the dose on measured recovery times. The evoked twitch response was allowed to recover spontaneously to 95 % of baseline height following each of these doses. Neuromuscular blockade was re-established with another bolus of 0.15 or 0.2 mg kg" 1 to achieve the baseline for mivacurium infusion. At approximately 5 % spontaneous recovery of the twitch response (i.e., at 95 % block), an infusion of mivacurium was commenced and controlled by an IMED volumetric infusion pump at an initial rate of 10 ug kg" 1 min" 1 and adjusted every 3 min until a stable 90-99 % evoked twitch suppression was obtained. When the infusion was discontinued, spontaneous recovery to control twitch height of 100% was obtained in 55 patients. Four recovery times were measured: from the time the infusion was discontinued to 25 % twitch height; 25-75 % recovery time; 25-95% recovery time; and 5-95 % recovery time.
For purposes of analysis the recovery indices were grouped according to the duration of the preceding infusion: 30-60 min, 60-90 min, 90-120 min, and more than 120 min. These times were compared with equivalent recovery times following the initial bolus dose of mivacurium. The infusion rate was measured in epochs of 3 min and the average rate was calculated for each patient. Venous or arterial blood samples were collected before induction of anaesthesia and dibucaine number and plasma cholinesterase activity were measured in 59 patients. The assays were performed according to the method of Kalow and Genest [5] . These were correlated with the average infusion rate of mivacurium required to maintain 95 (SEM 4) % block for each individual patient.
Group II (atracurium). Twenty-two patients of similar age and body weight consented to a study design similar to that for group I. Each received an initial bolus dose of atracurium 0.5 mgkg"
1 . When the twitch response recovered spontaneously to 5% of baseline (i.e., 95% twitch suppression), an infusion of atracurium was commenced at 10 ug kg" 1 min" 1 and adjusted every 3 min to maintain 95 (4) % twitch suppression.
Group III (vecuronium) . Eighteen patients were studied in the same manner as group II. Each patient received an initial bolus of vecuronium 0.1 mgkg" 1 . Following spontaneous recovery of the evoked twitch to 5 % of control, an infusion was started at a rate of 2.0 ug kg" 1 min" 1 and adjusted to maintain 95 (4) % depression of the evoked twitch.
In groups II and III, infusions lasted 1-2 h and all patients were allowed to recover spontaneously to 95 % twitch height. Measurements were made for recovery from 25-75 % and 5-95 % of initial control twitch. All patients recovered to 100% of control.
All data were analysed using analysis of variance, and correlated and uncorrelated t test with P < 0.05 being considered significant.
RESULTS
Infusion rates
The steady state infusion rates required to maintain twitch suppression within the range 90-99% were SJugkg" 1 min" 1 (range 2-14) for mivacurium, 7.9 ug kg" 1 min" 1 (4.8-12.0) for atracurium, and 1.2 ug kg" 1 min" 1 (0.9-4) for vecuronium. The steady state infusion rates were generally achieved after 10-12 min.
Cardiovascular effects
The cardiovascular effects of mivacurium were reported earlier [2] and a detailed account is in preparation. The cardiovascular response to miva-curium was minimal at 0.15 mg kg * (2 x ED 95 ), with an average peak change in mean arterial pressure of 7 % or less. At 0.2,0.25, or 0.3 mg kg" 1 (2.5-4 x ED 95 ), transient decreases in arterial pressure were noted in some individuals, accompanied by a brief (2-5 min) facial erythema. The general trend was related to both dose of mivacurium and the speed of injection. Decreases in arterial pressure were related directly to increases in plasma histamine concentration. For example, mean arterial pressure decreased by 13% and mean plasma histamine increased to 132% of baseline 2 min after the rapid bolus (10-15 s) injection of 0.25 mg kg" 1 . In contrast, during slower bolus administration (30-60 s of 0.25 mg kg" 1 ), arterial pressure decreased by 7.6 and 1.5%, respectively (P < 0.001, rapid v. 60-s bolus), and plasma histamine concentration did not change. No changes in arterial pressure or heart rate were noticed after the second bolus dose or following continuous infusion. The duration of infusion ranged from 29.5 to 286 min (n = 55).
Recovery times
Recovery times following bolus doses of mivacurium are summarized in table I. The mean (SEM) recovery time from discontinuing the infusion to 25% recovery of the twitch height (i.e., 75% twitch suppression) was 5.7 (0.3) min. The 25-75%, 25-95%, and 5-95% recovery times were 6.9 (0.3), 11.0 (0.4), and 14.5 (0.4) min, respectively. For each of the recovery variables, there was no significant difference between values determined following the bolus dose or following termination of infusion. Table II 
Correlation of infusion rate and plasma cholinesterase activity
Pearson's correlation coefficient between the average infusion rate of mivacurium for an individual patient and the plasma cholinesterase activity was statistically significant (P < 0.0042 and R = 0.42) ( fig. 1 ). In general, therefore, the average rate of infusion of mivacurium needed to maintain an appropriate level of steady state neuromuscular blockade was greater in patients with higher plasma cholinesterase activity. This is contrary to the poor correlation between plasma cholinesterase activity and the duration of block following bolus doses of mivacurium [6] .
DISCUSSION
The rationale for infusion of non-depolarizing neuromuscular blocking drugs has gained support partly from experience with infusions of suxamethonium and other drugs used in anaesthesia and intensive care such as vasoactive agents, lignocaine and opioids. In addition, the new intermediate acting neuromuscular blockers, atracurium and vecuronium, have unique pharmacokinetic and pharmacodynamic characteristics that make them suitable for infusion. With the new technology of improved monitoring of neuromuscular function and the ease of titrating the dose to effect by infusion, problems associated with the peaks and troughs of degrees of neuromuscular blockade can be avoided and thus more precise control of drug effects can be achieved. Mivacurium appears to exhibit desirable clinical pharmacological characteristics when used to maintain surgical relaxation by continuous i.v. infusion. Its neuromuscular blocking activity is transient and non-cumulative. Steady-state levels of block may be produced rapidly with minimal adjustment of the infusion rate and a consistent rate of recovery occurs irrespective of the duration of infusion. The steady-state infusion rate of 8.3 (0.7) ug kg" 1 min" 1 was not significantly different from that of atracurium.
Mivacurium has a predictable duration of action. There was no significant difference between the recovery time's 25-75 %, 25-95 %, or 5-95 % following bolus dose and those following infusions of up to 5 h, and there was no significant difference in these recovery times with different durations of infusion. The 25-75 % and 5-95 % recovery times of mivacurium are approximately 50 % those of atracurium and less than 50 % those of vecuronium for similar durations of infusion. However, comparing the recovery data of mivacurium and vecuronium from our study, it was found that the time from discontinuing the infusion of mivacurium to 25% recovery was 5.7 (0.3) min, compared with 12.7 min for vecuronium. In a study by Noeldge, Hinsken and Buzello [7] , the off-25% recovery time was 20 (10) min and the 25-75 % recovery index was 26 (6) min. This is almost four times longer than the 25-75 % recovery index of mivacurium (6.4 (0.2) min) observed after infusion of similar duration under identical anaesthetic techniques in the present study.
The recovery index of mivacurium did not change with the size of the bolus dose or duration of infusion. This is in contrast to findings with vecuronium. Feldman [8] found that the recovery index increased from 13.7 (SD 5.7) min to 30 (11.8) min when the bolus dose was increased from 0.1 to 0.25 mg kg" There was a statistically significant correlation between the average infusion rate of mivacurium for an individual patient and the patient's plasma cholinesterase activity (Pearson correlation coefficient, P < 0.0042). However, in a previous report [6] there was a poor correlation of plasma cholinesterase activity with duration of effect of mivacurium following bolus doses. This apparent discrepancy may be related to drug distribution processes to liver, kidney or other tissues which are present following bolus dosing. During steady-state infusion, the latter processes are constant.
In an earlier study with suxamethonium infusion [10] under nitrous oxide-oxygen-opioid anaesthesia, 24 of 32 patients studied developed phase II block. In 50% of these patients, the 25-95% and 5-95% recovery times were 12.7 (2.4) and 15.0 (3.0) min, respectively. These appear to be comparable to, if not longer than, the corresponding times for mivacurium of 11.0(0.5) and 14.5 (0.4) min (n = 55) for a similar duration of infusion (30-285 min). In the remaining 50% of the patients in the suxamethonium study, the time required to recover spontaneously from 5.0% to 75% was 31.0 (5.0) min. All these patients showed evidence of phase II block and all required antagonism of the residual neuromuscular blockade with anticholinesterase.
In summary, mivacurium shows excellent clinical characteristics for maintenance of neuromuscular blockade by continuous infusion, with no haemodynamic changes. The block is noncumulative. Spontaneous recovery requires only half the time of that following comparable durations of atracurium or vecuronium infusion. Recovery is faster than that of suxamethonium when infusions of similar duration are compared. Infusion of mivacurium may be useful especially for blockade during ambulatory or day-care surgery and during long procedures where rapid spontaneous recovery from neuromuscular block at the end of surgery is desirable.
